Depot antipsychotic medications in bipolar disorder: a review of the literature.

CONCLUSION: After a careful risk-benefit analysis, depot antipsychotics may be considered for the long-term control of mood episodes in bipolar patients who have relapsed due to medication non-adherence or who have failed to respond to standard therapies. Depot FGAs should be avoided in patients with a high burden of illness from depressive symptoms and particularly in those judged to be at high risk of suicide. The available data on depot formulations of SGAs indicate that they are efficacious in the maintenance treatment of bipolar illness without increasing the burden of the depressive pole of the illness, but further systematic studies are required to definitively assess this. PMID: 17688458 [PubMed - indexed for MEDLINE]
Source: Acta Psychiatrica Scandinavica Supplementum - Category: Psychiatry Tags: Acta Psychiatr Scand Suppl Source Type: research